Panel rules that Boston Scientific stents do not infringe Medinol patents
A World Intellectual Property Organization (WIPO) arbitration panel has ruled that Boston Scientific stents do not infringe any of the Medinol patents.
Medinol of Tel Aviv, Israel, which had requested the arbitration pursuant to the 2005 settlement agreement between the companies, alleged that the Liberte and Taxus Liberte stents infringed various U.S. and European patents held by Medinol.
In September 2005, Boston Scientific paid $750 million to settle claims that it broke its contract and stole the stent patent from its former business partner Medinol.
Under the terms of the settlement agreement, Medinol has a right to appeal to another WIPO panel, according to the Natick, Mass.-based Boston Scientific.
Medinol of Tel Aviv, Israel, which had requested the arbitration pursuant to the 2005 settlement agreement between the companies, alleged that the Liberte and Taxus Liberte stents infringed various U.S. and European patents held by Medinol.
In September 2005, Boston Scientific paid $750 million to settle claims that it broke its contract and stole the stent patent from its former business partner Medinol.
Under the terms of the settlement agreement, Medinol has a right to appeal to another WIPO panel, according to the Natick, Mass.-based Boston Scientific.